Document is current
Any future updates will be listed below
-
Authors
Ianevski, Aleksandr https://orcid.org/0000-0002-7780-482X
Nader, Kristen
Driva, Kyriaki
Senkowski, Wojciech https://orcid.org/0000-0001-8120-1944
Bulanova, Daria
Moyano-Galceran, Lidia https://orcid.org/0000-0001-9219-6394
Ruokoranta, Tanja https://orcid.org/0000-0003-4825-8599
Kuusanmäki, Heikki
Ikonen, Nemo https://orcid.org/0000-0003-4022-4394
Sergeev, Philipp
Vähä-Koskela, Markus
Giri, Anil K. https://orcid.org/0000-0003-0941-1458
Vähärautio, Anna https://orcid.org/0000-0003-4721-3954
Kontro, Mika
Porkka, Kimmo https://orcid.org/0000-0003-4112-5902
Pitkänen, Esa https://orcid.org/0000-0002-9818-6370
Heckman, Caroline A. https://orcid.org/0000-0002-4324-8706
Wennerberg, Krister https://orcid.org/0000-0002-1352-4220
Aittokallio, Tero https://orcid.org/0000-0002-0886-9769
- License Information
-
More Information
Article History
Received: 15 August 2023
Accepted: 27 September 2024
First Online: 3 October 2024
Competing interests
: KP: Research funding from BMS/Celgene, Incyte, Pfizer, and Novartis, unrelated to this study. CAH: Research funding from Kronos Bio, Novartis, Oncopeptides, WNTResearch, and Zentalis Pharmaceuticals for work unrelated to this study, honoraria from Amgen, and personal fees from Autolus. MK reports personal fees from Astellas Pharma, AbbVie, Bristol-Myers Squibb, Faron, Jazz Pharmaceuticals, Novartis and Pfizer and research funding from AbbVie outside the submitted work. TA: Research funding from the European Union’s Horizon Europe Research & Innovation program under grant agreement No 101057442. Views and opinions expressed in this document are those of the authors only. They do not necessarily reflect those of the European Union, which cannot be held responsible for the information it contains. All the other authors declare no potential competing interests.
